Skip to main content
Top
Published in: Calcified Tissue International 5/2012

01-11-2012 | Original Research

Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease

Authors: Laura E. Targownik, William D. Leslie, Rachel Carr, Ian Clara, Norine Miller, Linda Rogala, Lesley A. Graff, John R. Walker, Charles N. Bernstein

Published in: Calcified Tissue International | Issue 5/2012

Login to get access

Abstract

Persons with inflammatory bowel disease (IBD) are reported to have a high prevalence of osteoporosis and reduced bone mineral density (BMD) and to be at higher risk of fracture. The course of BMD loss over time is poorly characterized in persons with IBD. Eighty-six persons, stratified by age, were enrolled from a population-based longitudinal IBD cohort study to undergo BMD testing at baseline, with final BMD testing a mean of 4.3 years later. The proportion of subjects with significant change in BMD at the lumbar spine, total hip, and femoral neck was assessed, as were clinical, biochemical, and anthropomorphic changes. Vertebral radiographs were also obtained at baseline and at the end of follow-up in those aged 50 years and above to detect vertebral fractures. The change in BMD seen in this cohort of IBD patients was similar to the expected rate of BMD loss in the general population. Age >50 years, decreasing body mass index (BMI), and corticosteroid use were most notably correlated with BMD loss. Subjects aged <50 years did not have statistically significant declines in BMD. IBD symptom activity scores correlated poorly with BMD loss. Vertebral fractures were uncommon, with only two subjects out of 41 >50 years old developing a definite radiographic fracture over the course of follow-up. No major nonvertebral fractures were observed. Patients with IBD do not appear to have significantly accelerated BMD loss. Older age, decreasing BMI, and corticosteroid use may identify IBD patients at greater risk for BMD loss.
Literature
1.
go back to reference Bernstein CN (2006) Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4(2):152–156PubMedCrossRef Bernstein CN (2006) Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4(2):152–156PubMedCrossRef
2.
go back to reference Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG (2000) Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 232:43–47PubMed Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG (2000) Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 232:43–47PubMed
3.
go back to reference Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK (1995) A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37(1):71–76PubMedCrossRef Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK (1995) A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37(1):71–76PubMedCrossRef
4.
go back to reference Schulte C, Dignass AU, Mann K, Goebell H (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4(4):268–275PubMedCrossRef Schulte C, Dignass AU, Mann K, Goebell H (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4(4):268–275PubMedCrossRef
5.
go back to reference Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133(10):795–799PubMed Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133(10):795–799PubMed
6.
go back to reference Tilg H, Moschen AR, Kaser A, Pines A, Dotan I (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57(5):684–694PubMedCrossRef Tilg H, Moschen AR, Kaser A, Pines A, Dotan I (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57(5):684–694PubMedCrossRef
7.
go back to reference van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 243:59–64PubMedCrossRef van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 243:59–64PubMedCrossRef
8.
go back to reference Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN (2006) The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 4(12):1491–1501PubMedCrossRef Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN (2006) The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 4(12):1491–1501PubMedCrossRef
9.
go back to reference Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF (2006) The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 101(7):1559–1568PubMedCrossRef Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF (2006) The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 101(7):1559–1568PubMedCrossRef
10.
go back to reference Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN (2009) The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 104(7):1754–1763PubMedCrossRef Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN (2009) The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 104(7):1754–1763PubMedCrossRef
11.
12.
go back to reference Powell–Tuck J, Bown RL, Lennard-Jones JE (1978) A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13(7):833–837PubMedCrossRef Powell–Tuck J, Bown RL, Lennard-Jones JE (1978) A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13(7):833–837PubMedCrossRef
13.
go back to reference Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89(8):3651–3655PubMedCrossRef Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89(8):3651–3655PubMedCrossRef
14.
go back to reference Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11(8):680–687PubMedCrossRef Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11(8):680–687PubMedCrossRef
15.
go back to reference Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984–996PubMedCrossRef Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984–996PubMedCrossRef
16.
go back to reference Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D (2008) Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 178(13):1660–1668PubMedCrossRef Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D (2008) Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 178(13):1660–1668PubMedCrossRef
17.
go back to reference Warming L, Hassager C, Christiansen C (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13(2):105–112PubMedCrossRef Warming L, Hassager C, Christiansen C (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13(2):105–112PubMedCrossRef
18.
go back to reference Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M, Harlow SD (2002) Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 156(5):410–417PubMedCrossRef Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M, Harlow SD (2002) Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 156(5):410–417PubMedCrossRef
19.
go back to reference Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C (1997) Reduced bone density in patients with inflammatory bowel disease. Gut 40(2):228–233PubMed Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C (1997) Reduced bone density in patients with inflammatory bowel disease. Gut 40(2):228–233PubMed
20.
go back to reference Jahnsen J, Falch JA, Mowinckel P, Aadland E (2004) Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 39(2):145–153PubMedCrossRef Jahnsen J, Falch JA, Mowinckel P, Aadland E (2004) Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 39(2):145–153PubMedCrossRef
21.
go back to reference Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822PubMedCrossRef Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822PubMedCrossRef
22.
go back to reference Felson DT, Zhang Y, Hannan MT, Anderson JJ (1993) Effects of weight and body mass index on bone mineral density in men and women: the Framingham Study. J Bone Miner Res 8(5):567–573PubMedCrossRef Felson DT, Zhang Y, Hannan MT, Anderson JJ (1993) Effects of weight and body mass index on bone mineral density in men and women: the Framingham Study. J Bone Miner Res 8(5):567–573PubMedCrossRef
23.
go back to reference van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79(3):129–137PubMedCrossRef van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79(3):129–137PubMedCrossRef
24.
go back to reference Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112(5):352–364PubMed Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112(5):352–364PubMed
25.
go back to reference Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F (1995) Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10(2):250–256PubMedCrossRef Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F (1995) Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10(2):250–256PubMedCrossRef
26.
go back to reference Bernstein CN, Leslie WD, Leboff MS (2003) AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3):795–841PubMedCrossRef Bernstein CN, Leslie WD, Leboff MS (2003) AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3):795–841PubMedCrossRef
27.
go back to reference van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125(6):1591–1597PubMedCrossRef van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125(6):1591–1597PubMedCrossRef
28.
go back to reference Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Hoie O, Rydning A, Vatn MH (2011) Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 46(9):1081–1091PubMedCrossRef Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Hoie O, Rydning A, Vatn MH (2011) Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 46(9):1081–1091PubMedCrossRef
29.
go back to reference Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103(1):162–169PubMedCrossRef Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103(1):162–169PubMedCrossRef
30.
go back to reference Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55(3):426–431PubMedCrossRef Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55(3):426–431PubMedCrossRef
31.
go back to reference Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M (2008) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14(1):40–46PubMedCrossRef Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M (2008) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14(1):40–46PubMedCrossRef
Metadata
Title
Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease
Authors
Laura E. Targownik
William D. Leslie
Rachel Carr
Ian Clara
Norine Miller
Linda Rogala
Lesley A. Graff
John R. Walker
Charles N. Bernstein
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 5/2012
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-012-9650-1

Other articles of this Issue 5/2012

Calcified Tissue International 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.